CatalystMarker
← board

NNBXF

Revenue
pre-revenue
Liquidity
—
Runway
—
Shares 1y
—

Overview

Total Shares
48.41M

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 48,410,068
  • 2026-05-22424B5offering
  • 2026-05-22FWPoffering
  • 2026-05-21FWPoffering
  • 2026-05-21FWPoffering
  • 2026-05-20424B5offering
  • 2025-03-14EFFECTshelf_effective
  • 2025-03-06F-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.